enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. ‘A huge shock to the system’: Doctors warn about asthma ...

    www.aol.com/huge-shock-system-doctors-warn...

    GSK did price the authorized generic lower than branded Flovent; one package of Flovent HFA in the 110 microgram dose, for example, costs $273.83, about 50% more than the $177.99 wholesale ...

  3. Popular asthma inhaler will be discontinued Jan. 1. Here’s ...

    www.aol.com/news/popular-asthma-inhaler...

    The discontinuation aligns with a change to Medicaid rebates that may have had the inhaler’s manufacturer selling the drug at a loss. Popular asthma inhaler will be discontinued Jan. 1. Here’s ...

  4. List of withdrawn drugs - Wikipedia

    en.wikipedia.org/wiki/List_of_withdrawn_drugs

    Drug interactions, prolonged QT. [14] Drotrecogin alfa (Xigris) 2011 Worldwide Lack of efficacy as shown by PROWESS-SHOCK study [19] [20] [21] Ebrotidine: 1998 Spain Hepatotoxicity. [3] Efalizumab (Raptiva) 2009 Germany Withdrawn because of increased risk of progressive multifocal leukoencephalopathy [14] Encainide: 1991 UK, US Ventricular ...

  5. Fluticasone/salmeterol - Wikipedia

    en.wikipedia.org/wiki/Fluticasone/salmeterol

    Other side effects from this drug combination may include increased blood pressure, change in heart rate, an irregular heartbeat, increased risk of osteoporosis, cataracts, and glaucoma. [2] Studies have demonstrated the safety of inhaled fluticasone propionate in children.

  6. Fluticasone furoate/vilanterol - Wikipedia

    en.wikipedia.org/wiki/Fluticasone_furoate/vilanterol

    In 2013, the drug was approved for use in the United States by the Food and Drug Administration (FDA) for long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and emphysema, [6] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma. [7]

  7. GlaxoSmithKline Dives on Weak Growth - AOL

    www.aol.com/2012/04/25/glaxosmithkline-dives-on...

    LONDON -- "Big pharma" giant GlaxoSmithKline (NYS: GSK) slightly disappointed its owners today, as its latest results revealed low growth in turnover and earnings. GSK's slow growthAs soon as GSK ...

  8. GSK's asthma drug Nucala meets main goal in study on ... - AOL

    www.aol.com/news/gsks-asthma-drug-nucala-meets...

    (Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or ...

  9. GSK1016790A - Wikipedia

    en.wikipedia.org/wiki/GSK1016790A

    GSK1016790A (aka GSK101) is a drug developed by GlaxoSmithKline which acts as a potent and selective agonist for the TRPV4 receptor. It has been used to study the role of TRPV4 receptors in the function of smooth muscle tissue, particularly that lining blood vessels, lymphatic system, and the bladder.